Celldex Therapeutics (CLDX) Posts Narrower than Expected Q4 Loss

March 7, 2012 7:02 AM

Celldex Therapeutics (NASDAQ: CLDX) reported Q4 EPS of ($0.24), $0.04 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.43 million versus the consensus estimate of $2.26 million.

For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.

No results found